Bharat Biotech announced on Tuesday a collaboration with Bilthoven Biologicals B.V., based in the Netherlands and a wholly-owned subsidiary of the Serum Institute of India, to enhance the production and supply security of oral polio vaccines (OPVs). According to the agreement between the two companies, Bharat Biotech will procure drug substances necessary for OPV production to be supplied within India and globally.
Under this partnership, Bharat Biotech and Bilthoven Biologicals (BBio) will work together to obtain the regulatory approvals and licenses needed for commercial OPV manufacturing in India, using drug substances manufactured by BBio in the Netherlands. This collaboration aims to ensure a stable supply of oral polio vaccines, contributing to the global effort to eradicate polio.
Krishna Ella, Executive Chairman of Bharat Biotech, emphasized that this collaboration demonstrates the cooperation between vaccine companies in securing the supply of oral polio vaccines, aligning with the goal of eradicating polio. Adar Poonawalla, CEO of the Serum Institute of India, reiterated the vision to eradicate polio worldwide, aiming to reduce the impact of this disease on vulnerable populations.
The collaboration between Bharat Biotech and Bilthoven Biologicals supports the initiative to achieve a polio-free world, especially as the global polio eradication initiative enters a critical phase. Oral polio vaccines have been a crucial component of India's Universal Immunisation Programme for many years, with Bharat Biotech being one of the primary suppliers to immunization programs worldwide.
.jpg "Artificial Intelligence to Revolutionize Advanced Chip Design")
